Telomir Pharmaceuticals, Inc. (TELO): Net Income

Annual figures by period end, from SEC filings.

-$10.41M

Year ended 2025-12-31

-$5.88M

Trailing 12 months to 2026-06-30

2022-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$10.41M	n/m	2026-03-17, From 2025-01-01
2024-12-31	-$16.53M	n/m	2026-03-17, From 2024-01-01
2023-12-31	-$13.07M	n/m	2025-02-04, From 2023-01-01
2022-12-31	-$854.1K	n/a	2024-03-29, From 2022-01-01

Net Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Telomir Pharmaceuticals, Inc. (TELO)	2025-12-31	-$10.41M	n/m
Ensysce Biosciences, Inc. (ENSC)	2025-12-31	-$10.18M	n/m
Matinas BioPharma Holdings, Inc. (MTNB)	2025-12-31	-$10.35M	n/m
Oncolytics Biotech Inc (ONCY)	2025-12-31	-$28.76M	n/m
Rocket One Inc. (RKTO)	2025-12-31	-$12.47M	n/m
Silo Pharma, Inc. (SILO)	2025-12-31	-$4.23M	n/m
Cannapharmarx, Inc. (CPMD)	2025-12-31	-$11.13M	n/m
Acurx Pharmaceuticals, Inc. (ACXP)	2025-12-31	-$7.97M	n/m
CV Sciences, Inc. (CVSI)	2025-12-31	-$958.0K	n/m

Compare TELO, ENSC, MTNB, ONCY side by side · Screen every company in Pharmaceutical Preparations ↗